Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7700MR)

This product GTTS-WQ7700MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7700MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5154MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ15970MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ3943MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ8182MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ138MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ1532MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ8948MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14400MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW